Enzyme
FDA Approves Roche’s PATHWAY HER2 Test for HER2-Ultralow Metastatic Breast Cancer
Roche, PATHWAY HER2 (4B5) test, FDA approval, HER2-ultralow, metastatic breast cancer, companion diagnostic, Enhertu, personalized medicine
J&J’s Rybrevant-Lazcluze Combo Demonstrates Superior Survival Benefit Over Tagrisso in EGFR-Mutated NSCLC
Rybrevant, Lazcluze, Tagrisso, NSCLC, EGFR mutation, overall survival, Phase III MARIPOSA trial, chemotherapy-free regimen
Bioptimus Secures $76M Funding to Develop Revolutionary AI Foundation Model for Biology
Bioptimus, AI foundation model, biology, funding, Cathay Innovation, GPT of biology, biological research, pharmaceutical industry, biotech, medical innovation.
I-Mab Reprioritizes Pipeline, Halts CD73 Antibody Development to Focus on Givastomig
I-Mab, pipeline reshuffle, CD73 antibody, uliledlimab, givastomig, CLDN18.2 x 4-1BB bispecific antibody, cancer immunotherapy, metastatic gastric cancers
I-Mab Shifts Focus Away from CD73 Program to Pursue Strategic Options in CLDN18.2 Space
I-Mab, CD73, CLDN18.2, Sanofi, Strategic Options, Biotech Development
FDA Approves Subcutaneous Formulation of Bristol Myers’ Opdivo for Solid Tumor Indications
FDA approval, subcutaneous Opdivo, Bristol Myers Squibb, cancer treatment, immunotherapy, nivolumab, hyaluronidase
AstraZeneca’s Tagrisso Expands EU Approval for NSCLC Treatment
AstraZeneca, Tagrisso, NSCLC, EU approval, EGFR mutations, lung cancer treatment
FDA Rejects Subcutaneous Version of J&J’s Lung Cancer Drug Rybrevant Due to Manufacturing Concerns
FDA rejection, J&J, Subcutaneous Rybrevant, Manufacturing issues, Lung cancer drug, Non-small cell lung cancer (NSCLC), Epidermal growth factor receptor (EGFR) mutations
Narsoplimab Demonstrates Significant Survival Benefit in Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
Narsoplimab, Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA), Lectin Pathway Inhibition, MASP-2 Inhibitor, Rare Disease Treatment, Overall Survival Improvement
Pfizer’s IBRANCE Demonstrates Significant Efficacy in HR+, HER2+ Metastatic Breast Cancer
IBRANCE (palbociclib), HR+/ HER2+ metastatic breast cancer, Phase 3 PATINA trial, Progression-free survival (PFS), Standard-of-care therapies, Anti-HER2 therapy, Endocrine therapy